title: Probiotics determine hypolipidemic and antioxidant effects in hyperlipidemic hamsters.
abstract: METHODS
  Hyperlipidemia, hyperglycemia, and the oxidative stress are among the known risk factors of atherosclerosis. Our aim was to assess the hypolipidemic and antioxidant effects of a probiotic mix (Lactobacillus acidophilus and Bifidobacterium animalis) in hyperlipidemic hamsters (HL).
  
  
  RESULTS
  Male Golden Syrian hamsters developed hyperlipidemia after 21 weeks of fat diet. For the last 5 weeks of experiment, ten HL were treated with the probiotic mix (HLP), ten received water (HL). Ten animals received standard chow (N). Increase of plasma total cholesterol (TC), triglycerides (TG), phospholipids (PL), oxidized LDL, glucose, of 4-hydroxynonenal (4-HNE) in plasma, liver, and myocardium, and of intestinal Niemann Pick C1 like 1 (NPC1L1) and microsomal TG transfer protein (MTTP) expression was observed in HL versus N. The probiotic mix decreased plasma TC, TG, PL, oxidized LDL, 4-HNE, and glucose levels and increased paraoxonase-1 activity, decreased NPC1L1 and MTTP protein expression compared to HL. In HLP liver, a significant reduction of TC, TG, and fatty acids was observed. PL increased and 4-HNE levels decreased in the liver and myocardium of HLP versus HL.
  
  
  CONCLUSIONS
  Our data support the administration of probiotics to humans because of their hypolipidemic (through decreasing intestinal NPC1L1 and MTTP) and antioxidant effects (stimulating HDL-associated paraoxonase-1).
authors.affiliation: Lipidomics Department, Institute of Cellular Biology and Pathology "Nicolae Simionescu" of the Romanian Academy, Bucharest, Romania.
authors.forename: Camelia Sorina
authors.initials: CS
authors.lastname: Stancu
authors.forename: Gabriela Maria
authors.initials: GM
authors.lastname: Sanda
authors.forename: Mariana
authors.initials: M
authors.lastname: Deleanu
authors.forename: Anca Volumnia
authors.initials: AV
authors.lastname: Sima
mesh_terms: D000818:Animals; D000975:Antioxidants / Q000494:pharmacology*; D001644:Bifidobacterium; D002352:Carrier Proteins / Q000378:metabolism; D004195:Disease Models, Animal; D006949:Hyperlipidemias / Q000188:drug therapy* / Q000378:metabolism*; D007779:Lactobacillus acidophilus; D050356:Lipid Metabolism / Q000187:drug effects; D008055:Lipids / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism; D008647:Mesocricetus; D009206:Myocardium / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D019936:Probiotics / Q000494:pharmacology*
chemical_list: D000975:Antioxidants; D002352:Carrier Proteins; D008055:Lipids; D008077:Lipoproteins, LDL; D008565:Membrane Proteins
keywords: Atherosclerosis; Hyperlipidemia; Lipoproteins; Oxidative stress; Probiotics